Officials at NXP Semiconductors N.V. (NASDAQ:NXPI) and Freescale Semiconductor, Ltd. announced that the two companies have signed a definitive agreement that will have NXP merge with Freescale in a transaction valued at just over $40 billion. Freescale’s PowerPC chips fuel computing and signal processing in many defense electronics applications such as avionics, radar, and electronic warfare. On Friday shares of NXP Semiconductors NV (NASDAQ:NXPI) closed at $104.67. Company’s sales growth for last 5 years was 9.90% and EPS growth for next 5 years is recorded as 22.53%.
On March 11, TG Therapeutics Inc. (NASDAQ:TGTX) reported a loss of $18.8 million in its fourth quarter. For the year, the company reported that its loss widened to $55.8 million, or $1.64 per share. Revenue was reported as $152.4 million. TG Therapeutics, Inc. (NASDAQ:TGTX) in last trading activity advanced 8.38% to close at $17.33. Company weekly performance is 14.31% while its quarterly performance stands at 19.93%. TG Therapeutics, Inc. (NASDAQ:TGTX) is -8.21% away from its 52 week high.
Superior Drilling Products, Inc. (NYSEMKT:SDPI) announced preliminary results for the fourth quarter and full year 2014. Fourth quarter 2014 revenue was $6.1 million, an increase of 5.2% from the third quarter 2014, on increased market penetration of the Company’s innovative Drill-N-Ream (DNR) well bore conditioning tool. On last trading day Superior Drilling Products, Inc. (NYSEMKT:SDPI) fell -1.36% to close at $2.91. Its volatility for the week is 3.31% while volatility for the month is 5.43%. Superior Drilling Products, Inc. (NYSEMKT:SDPI) monthly performance is -15.16%.
Merck & Co Inc (NYSE:MRK) said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug. Merck on Friday said it expects a so-called complete response letter from the U.S. Food and Drug Administration by April 22. On Friday shares of Merck & Co. Inc. (NYSE:MRK) closed at $56.20. Company’s sales growth for last 5 years was 9.00% and EPS growth for next 5 years is recorded as 6.93%.
JPMorgan Chase & Co. reissued their neutral rating on shares of Smith & Nephew plc (NYSE:SNN) in a research report released on Wednesday morning. On last trading day Smith & Nephew plc (NYSE:SNN) fell -1.12% to close at $33.50. Its volatility for the week is 1.04% while volatility for the month is 1.34%. SNN’s sales growth for past 5 years was 4.10% and its EPS growth for past 5 years was 1.10%. Smith & Nephew plc (NYSE:SNN) monthly performance is -5.82%.